港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

58.000

-1.000-1.69%

成交量：38.89万

成交额：2,266.24万

市值：115.42亿

市盈率：-28.88

高：59.100

开：58.850

低：57.750

收：59.000

52周最高：83.600

52周最低：51.600

股本：1.99亿

香港流通股本：1.53亿

量比：0.84

换手率：0.25%

股息：- -

股息率：- -

每股收益(LYR):-2.008

净资产收益率：--

总资产收益率：--

市净率：100.66

市盈率(LYR):-28.88

市销率: - -

数据加载中...

总览公司新闻资讯公告

每日卖空追踪 | 维立志博-B 11月17日卖空量成交2.87万股，卖空比例为7.38%

药企赴港IPO火爆，半个月8家递表，基石投资者“快看不过来了”

每日卖空追踪 | 维立志博-B 11月14日卖空量成交1.9万股，卖空比例为3.54%

维立志博-B11月14日主力净流出147.5万元散户资金买入

维立志博-B盘中异动急速拉升5.05%

解析！16家江苏创新药公司Q3获融资

【券商聚焦】信达证券维持维立志博(09887)“买入”评级指公司资金充裕充分保障多条管线开发

医药领域，这些潜力赛道即将爆发！

【信达医药】维立志博研发日跟踪点评：崭露头角，蓄势待发

唐爱金团队研究

维立志博-B11月11日主力净流出56.5万元散户资金买入

透视81家创新药企三季报：亏损收窄医保放量BD增长释放什么信号？

三国杀：维立志博、德琪医药和迈威生物

建国路128号

维立志博-B(09887)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药

中邮证券-医药生物行业周报：自免口服药物市场存在供需错配，关注NME带来的积极转变-251110

维立志博研发日：引领下一代肿瘤免疫治疗

中国创新药“生死局”：一边是IPO，一边是ICU

腾讯新闻潜望

港股公告掘金 | 乐舒适明日上市富智康集团预期年度财务业绩大幅改善

维立志博-B(09887)获纳入MSCI全球小型股指数

【信达医药】周观点：Q3业绩季收官，看好制药装备受益海外需求景气周期

唐爱金团队研究

维立志博-B11月05日获主力加仓39.3万元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/09887/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":58,"timestamp":1763366895006,"preClose":59,"halted":0,"volume":388920,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"未开盘","change":-1,"latestTime":"11-17 16:08:15","open":58.85,"high":59.1,"low":57.75,"amount":22662445,"amplitude":0.022881,"askPrice":58.35,"askSize":1400,"bidPrice":58,"bidSize":3200,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":59,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.8430780541765974,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":0.8430780541765974,"shares":199000000,"dividePrice":0,"high":59.1,"amplitude":0.022881,"preClose":59,"low":57.75,"week52Low":51.6,"pbRate":"100.66","week52High":83.6,"institutionHeld":0,"latestPrice":58,"committee":0.391304,"eps":-2.008042,"divideRate":0,"volume":388920,"delay":0,"ttmEps":-1.858667,"open":58.85,"prevYearClose":35,"prevWeekClose":59,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":59.75,"twentyDayClose":65,"sixtyDayClose":70.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762531200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-14","current":-31.205159,"percent":0.896104,"low":-50.052922,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"high":-34.030535,"avg":-41.326136,"sd":3.17833,"marketCap":11734616200},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200}],"updateTime":1763410600146},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584462576","title":"每日卖空追踪 | 维立志博-B 11月17日卖空量成交2.87万股，卖空比例为7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584462576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584462576?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:30","pubTimestamp":1763368238,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月17日，跌1.69%，卖空量成交2.87万股，较上一交易日减少0.35%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163615a4a72f33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163615a4a72f33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2583363717","title":"药企赴港IPO火爆，半个月8家递表，基石投资者“快看不过来了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2583363717","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583363717?lang=zh_cn&edition=fundamental","pubTime":"2025-11-15 16:43","pubTimestamp":1763196217,"startTime":"0","endTime":"0","summary":"“我们正在中国香港进行IPO路演，但这段时间药企扎堆申报港股IPO，已形成了‘堰塞湖’，基石投资者和锚定投资者都快看不过来了，我们遭遇路演排队。”有赴港IPO药企人士对第一财经记者透露。今年以来，港股医药二级市场的复苏，提振了企业们IPO融资热情。根据Choice金融终端数据，截至11月14日，港股的医疗保健板块今年累计迎来了23家企业成功上市，而去年同期仅有8家企业上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://hk.eastmoney.com/news/11792,202511153565388760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/news/11792,202511153565388760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LU0594300179.USD","LU1934453819.USD","300760","LU1023057109.AUD","LU2097828714.EUR","LU0405327494.USD","LU1580142542.USD","LU2153592121.USD","IE0031814852.USD","LU2097828805.USD","HK0000252160.HKD","LU0359201612.USD","688506","LU1979443071.USD","LU2580892862.HKD","LU1328615791.USD","LU1688375341.USD","LU1720050803.USD","LU2153591404.USD","02595","LU2148510915.USD","LU1146622755.USD","09939","GIC","09606","LU1781817850.SGD","BK1515","HK0000500386.USD","SGXZ81163826.USD","02617","LU1734074674.USD","LU0605514214.HKD","LU2213484517.USD","HK0000252152.HKD","LU1064130708.USD","LU2097828474.EUR","LU1655091616.SGD","BK4104","SGXZ49509284.SGD","09887","02591","IE00B29SXG58.USD","LU1064131003.USD","LU0572944931.SGD","300558","02615","BK0196","LU0823426308.USD","LU1997244956.HKD","600276"],"gpt_icon":0},{"id":"2583689715","title":"每日卖空追踪 | 维立志博-B 11月14日卖空量成交1.9万股，卖空比例为3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689715","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583689715?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:30","pubTimestamp":1763109041,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间11月14日，跌0.84%，卖空量成交1.9万股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164202a4a11cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164202a4a11cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2583689796","title":"维立志博-B11月14日主力净流出147.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689796","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583689796?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:16","pubTimestamp":1763108161,"startTime":"0","endTime":"0","summary":"11月14日, 维立志博-B股价跌0.84%，报收59.00元，成交金额3174.6万元，换手率0.35%，振幅6.22%，量比1.18。维立志博-B今日主力资金净流出147.5万元，上一交易日主力净流入49.2万元。该股近5个交易日上涨0.94%，主力资金累计净流入632.4万元；近20日主力资金累计净流入613.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141624099768f5fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141624099768f5fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2583616559","title":"维立志博-B盘中异动 急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583616559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583616559?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 10:55","pubTimestamp":1763002548,"startTime":"0","endTime":"0","summary":"2025年11月13日早盘10时55分，维立志博-B股票出现波动，股价快速拉升5.05%。截至发稿，该股报60.300港元/股，成交量15.41万股，换手率0.10%，振幅4.44%。维立志博-B股票所在的生物技术行业中，整体涨幅为4.57%。维立志博-B公司简介：我们是一家临床阶段生物科技公司,致力于创新疗法的发现、开发及商业化,以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113105548a49dd25b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113105548a49dd25b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2582430802","title":"解析！16家江苏创新药公司Q3获融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2582430802","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582430802?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 17:13","pubTimestamp":1762938791,"startTime":"0","endTime":"0","summary":"2025年第三季度，江苏创新药生态继续展现韧性与分层活力。据统计，Q3至少有16家江苏创新药公司获融资，已披露金额合计超25亿元。本季度亿元及以上融资事件共5起，在总额中占比较高。7家获融资公司布局抗肿瘤相关项目，且多为实体瘤与血液瘤并行布局；同时女性健康（4起）、中枢神经（3起）、代谢疾病（3起）、皮肤科（3起）等领域融资活跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112192029a6f45ac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112192029a6f45ac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1110","09887","02116"],"gpt_icon":0},{"id":"2582109113","title":"【券商聚焦】信达证券维持维立志博(09887)“买入”评级 指公司资金充裕充分保障多条管线开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2582109113","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582109113?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 10:48","pubTimestamp":1762915704,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达证券发研报指，维立志博 2025年11月9日研发日更新多个产品研发进展。大样本临床数据表明：LBL-024彻底解决4-1B乙肝毒性问题。LBL-024在NSCLC领域崭露头角，具备成为二代IO基石药物的潜力。资金充裕充分保障多条管线开发。截止到2025H1公司现金及现金等价物4.22亿元，除此之外，2025年7月公司首次公开发行募资所得净额13.63亿港币，充裕的资金储备为公司多条研发管线的快速推进提供了坚强保障。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969485","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601059","09887"],"gpt_icon":0},{"id":"2582366645","title":"医药领域，这些潜力赛道即将爆发！","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366645","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366645?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 19:13","pubTimestamp":1762859617,"startTime":"0","endTime":"0","summary":"2025年，默克宣布与加拿大AI制药公司Variational AI达成协议，潜在交易总价值达3.49亿美元，默克将利用其AI药物发现平台设计和优化针对两个未公开靶点的小分子候选药物。礼来的Orforglipron在全球口服小分子中进展最快，预计今年年底递交上市申请（图3），国内企业如恒瑞医药、华东医药、闻泰科技等也在该领域积极布局，部分管线已进入临床中后期，展现出较强的出海潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111200654a6f1f725&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111200654a6f1f725&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z4B17.USD","09887","BK4187","BK4007","BK4006","06998","IE00B7SZL793.SGD","IE0031619046.USD","NVO","BK4532","02105","LU2065731478.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","IE00B66KJ199.SGD","IE00BZ1G4Q59.USD","BK4585","LU0154236417.USD","BK4588","01276","LU0963586101.USD","BK4599","CRS"],"gpt_icon":1},{"id":"2582391951","title":"【信达医药】维立志博研发日跟踪点评：崭露头角，蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391951","media":"唐爱金团队研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582391951?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 19:06","pubTimestamp":1762859175,"startTime":"0","endTime":"0","summary":"事件：维立志博2025年11月9日研发日更新多个产品研发进展点评：大样本临床数据表明：LBL-024彻底解决4-1B乙肝毒性问题。LBL-024在NSCLC领域崭露头角，具备成为二代IO基石药物的潜力。此次研发日公司首次发布了LBL-024联合化疗治疗非小细胞肺癌的小样本临床数据，18例可评估疗效的患者整体ORR=50%，DCR=94.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111201904a499d8fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111201904a499d8fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","09939","BK1574","09887"],"gpt_icon":0},{"id":"2582391954","title":"维立志博-B11月11日主力净流出56.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582391954?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 16:15","pubTimestamp":1762848958,"startTime":"0","endTime":"0","summary":"11月11日, 维立志博-B股价跌0.67%，报收59.35元，成交金额1805.5万元，换手率0.20%，振幅2.85%，量比0.52。维立志博-B今日主力资金净流出56.5万元，上一交易日主力净流入998.5万元。该股近5个交易日上涨5.18%，主力资金累计净流入1146.0万元；近20日主力资金累计净流出524.7万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116222994fd382c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116222994fd382c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582357420","title":"透视81家创新药企三季报：亏损收窄医保放量BD增长释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582357420","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582357420?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 15:35","pubTimestamp":1762846544,"startTime":"0","endTime":"0","summary":"整体来看，81家A股创新药上市公司归母净利润实现同比增长，增幅达13.84%。数据显示，近年来，中国创新药企业国际授权合作数量不断增加。截至10月21日，2025年中国创新药对外许可交易115起，总金额1012.4亿美元，远超2024年全年519亿美元。11月3日，为期五天的2025年国家医保谈判收官，今年的国家医保谈判，在延续医保目录常规调整机制的基础上，首次引入商保创新药目录新机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","09887","BK1574","09969","06978","01276","BK1161","02509"],"gpt_icon":0},{"id":"2582959804","title":"三国杀：维立志博、德琪医药和迈威生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2582959804","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582959804?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 20:36","pubTimestamp":1762778175,"startTime":"0","endTime":"0","summary":"今天来盘三家不同的公司，维立志博、德琪和迈威。维立志博绕过了当下主流“冷肿瘤”的技术路径，权力押注了“免疫+”、“TCE+”两大方向；德琪医药在面对核心产品“上市即巅峰” 的困局，展现出极强的“精益运营” 纪律，勒紧裤带，只为“差异化”的自研管线搏一个未来；迈威生物在“乏善可陈” 的质疑声中，借着“A+H”带来的新弹药，在BD的牌桌上掀起了10亿美金的巨浪。德琪医药的“开局”并不顺利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110205251a497571e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110205251a497571e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06996","BK1191","BK1574","BK1583","09887"],"gpt_icon":0},{"id":"2582825495","title":"维立志博-B(09887)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825495","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582825495?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:42","pubTimestamp":1762764148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价奥帕替苏米单抗用于一线治疗肝细胞癌的II期临床研究首例患者已成功用药，标志着该核心产品适应症拓展高效推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗肝细胞癌患者的疗效及安全性。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-024于一线治疗肝细胞癌II期试验的首例患者用药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2582846287","title":"中邮证券-医药生物行业周报：自免口服药物市场存在供需错配，关注NME带来的积极转变-251110","url":"https://stock-news.laohu8.com/highlight/detail?id=2582846287","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582846287?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 12:02","pubTimestamp":1762747320,"startTime":"0","endTime":"0","summary":"本周主题本周我们探讨自免领域的口服药物市场价值。自免药物的口服需求庞大，现有疗法存在供需错配。参考NatureReviews，2023年银屑病整体市场为270亿美金，其中口服药物为25亿美金，仅占9%。药物市场主要由IL-23、IL-17和TNF等生物类抑制剂占据。从需求端来看，75%接受注射疗法的病人存在转换为口服的意愿。恒生医疗保健指数下跌2.39%，板块整体跑输恒生指数3.68pct。在恒生12个一级子行业中，医疗保健行业周涨跌幅排名为第12位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","IE00B5MMRT66.SGD","LU0348783233.USD","LU0417516738.SGD","LU0417516571.SGD","LU0561508036.HKD","09887","BK1161","LU0348766576.USD","03759","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","02509","06978","BK1574","LU0348827113.USD","LU2399975544.HKD","LU1794554557.SGD","LU2476274308.USD","LU0348825331.USD","LU0348767384.USD","IE00B543WZ88.USD","LU0348735423.USD","LU0634319403.HKD","LU0348784397.USD","09606","IE00BPRC5H50.USD","02157","01276","LU2778985437.USD","LU0540923850.HKD","LU2476274720.SGD","LU1961090484.USD"],"gpt_icon":0},{"id":"2582849032","title":"维立志博研发日：引领下一代肿瘤免疫治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2582849032","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582849032?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 07:56","pubTimestamp":1762732562,"startTime":"0","endTime":"0","summary":"IO2.0+TCE+ADC2.0全面布局下一代免疫疗法维立志博致力于创新疗法的发现、开发及商业化，聚焦冷肿瘤、免疫耐药、拖尾问题等核心挑战，重点解决PD-1/PD-L1抗体为代表的现有疗法不能治疗的疾病。维立志博拥有高效的多功能平台和技术能力整合的自主研发体系，从IO低反应率和耐药的分子机制出发，聚焦三大技术平台的迭代和进化，定义下一代免疫治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110075856a6ede11e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110075856a6ede11e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582849703","title":"中国创新药“生死局”：一边是IPO，一边是ICU","url":"https://stock-news.laohu8.com/highlight/detail?id=2582849703","media":"腾讯新闻潜望","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582849703?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 07:25","pubTimestamp":1762730700,"startTime":"0","endTime":"0","summary":"中国创新药资本市场发展不过十年，但已饱尝周期的甜头与苦涩。再加上创新药出海频传大额交易，医药板块迎来强势反弹，恒生生物科技指数年初至今的升幅一度超过100%。“现在评估Pre-IPO项目，一定会先看CFO是谁。”医药魔方数据显示，2024年中国创新药一级市场融资额仅有2021年的五分之一，IPO次数和募资金额也创十年新低。加上中国创新药同质化严重，一个热门靶点可能有上百家公司在争夺，都在争取几家顶尖肿瘤医院做临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110072849975ee55d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110072849975ee55d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","09887","09969","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2582950894","title":"港股公告掘金 | 乐舒适明日上市 富智康集团预期年度财务业绩大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2582950894","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582950894?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 19:58","pubTimestamp":1762689534,"startTime":"0","endTime":"0","summary":"【重大事项】乐舒适(02698):香港公开发售获1813.77倍认购 预计11月10日上市中伟新材(02579)11月7日至11月12日招股 预计11月17日上市百利天恒(02615)11月7日至11月12日招股 预计11月17日上市昊海生物科技(06826)拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权维立志博-B(09887)获纳入MSCI全球小型股指数恒瑞医药(01276)：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1160","LU0359201885.HKD","BK1612","BK1161","BK1531","BK1104","BK1167","LU0359201612.USD","BK1191","LU1023057109.AUD","09887","BK1508","LU0359202008.SGD","02698","LU2543165471.USD","02038","01276","BK1526","00434","BK1504"],"gpt_icon":0},{"id":"2581024901","title":"维立志博-B(09887)获纳入MSCI全球小型股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581024901?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 12:06","pubTimestamp":1762488361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，公司将获纳入MSCI全球小型股指数成份股，自2025年11月24日收市后生效。MSCI全球小型股指数由Morgan Stanley Capital International(MSCI)编制，旨在衡量市场小型股板块的表现。MSCI指数被众多国际专业投资机构广泛参考。董事会认为，公司获纳入MSCI全球小型股指数反映全球投资者对公司经营表现及发展潜力的认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109391861.USD","LU0289961442.SGD","LU0672654240.SGD","LU2210149790.SGD","MSCI","BK1161","LU0390134368.USD","LU0175139822.USD","LU2095319765.USD","LU0708995401.HKD","09887","LU1691799644.USD","LU0511384066.AUD","LU1804176565.USD","LU0289739343.SGD","LU2265009873.SGD","LU0320765059.SGD","IE00BKPKM429.USD","BK4585","LU1267930730.SGD","LU2210150020.SGD","BK4588","LU0289960550.SGD","BK4112"],"gpt_icon":0},{"id":"2581774375","title":"【信达医药】周观点：Q3业绩季收官，看好制药装备受益海外需求景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581774375","media":"唐爱金团队研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581774375?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 21:51","pubTimestamp":1762350688,"startTime":"0","endTime":"0","summary":"周观点：通过对 Q3 报的分析，创新药、CXO、医疗耗材等板块景气度相对较高。此外，自Q3起医疗器械板块已呈现业绩改善趋势。在中长期维度，我们持续推荐高景气赛道，制药装备、创新药、CXO及生命科学上游产业链、高端器械。在短期维度，我们认为可关注Q4 流感条线。制药装备受益于海外需求提升：我们跟踪到海外制药进入投资景气上行周期，建议关注森松国际、东富龙、楚天科技。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105235432a6e39d9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105235432a6e39d9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2097828474.EUR","LU2097828805.USD","LU2097828714.EUR","02268","BK1515","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","09887","03347","BK1191","LU2242644610.SGD","LU2097828631.EUR","02172","01066","06821","BK1583","86618","01276","BK1161","LU2488822045.USD","02315","03759","01530","LU0455707207.USD","02155","BK1589","01548","01877","00853","01477","00950","00241","LU2328871848.SGD","01801","09939"],"gpt_icon":0},{"id":"2581703741","title":"维立志博-B11月05日获主力加仓39.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581703741","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581703741?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 16:16","pubTimestamp":1762330566,"startTime":"0","endTime":"0","summary":"11月05日, 维立志博-B股价涨0.63%，报收56.30元，成交金额3181.0万元，换手率0.37%，振幅9.03%，量比0.63。维立志博-B今日主力资金净流入39.3万元，上一交易日主力净流入203.2万元。该股近5个交易日下跌4.24%，主力资金累计净流入480.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出874.5万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516232397555819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516232397555819&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":151,"code":"91000000","status":"200"}]}}